Back to the list
Congress: ECR25
Poster Number: C-28368
Type: Poster: EPOS Radiologist (educational)
Authorblock: J. Hunter, J. Burns, M. Fitzsimons, D. Caldwell, M. J. O'Connell, P. Gilligan; Dublin/IE
Disclosures:
Jonathan Hunter: Nothing to disclose
Jane Burns: Nothing to disclose
Michael Fitzsimons: Nothing to disclose
David Caldwell: Nothing to disclose
Martin Joseph O'Connell: Nothing to disclose
Paddy Gilligan: Nothing to disclose
Keywords: Hybrid Imaging, Molecular imaging, Oncology, PET-CT, Education, Molecular imaging, Education and training, Multidisciplinary cancer care
Learning objectives Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in the majority of prostate cancers 1 . This overexpression enables the identification of prostate cancer and metastases using radiolabelled small molecules that bind with high affinity. In recent years, it has rapidly become an important diagnostic tool in the care of men with prostate cancer.The aims of this educational poster is to highlight interesting and diagnostically challenging cases that Prostate-specific membrane antigen (PSMA) PET-CT imaging has aided in...
Read more Background Since its introduction, PSMA PET/CT has become a vital tool in in the primary diagnosis and staging prostate cancer, as well as, in detecting biochemical recurrence after curative treatment and in metastasis-directed therapy. It has led to a shift away from traditional algorithms, introduced the field of theranostics, and brought attention to as many uncertainties as it has advancements. The advent of PSMA PET/CT has highlighted the limitations of our conventional staging imaging and may even have a greater influence...
Read more Findings and procedure details In order to accurately interpret nuclear medicine studies, a knowledge of the normal physiological distribution of the radiotracer is required. PSMA expression is present in normal prostatic tissue, though at a low level, and can also be found in the salivary and lacrimal glands, nasal cavity, larynx, liver, spleen, intestines, kidneys, and sympathetic ganglia 2 . Below is an image of the normal radiotracer distribution for [18F]-PSMA PET.   [fig 1]  In our institution, we starting using [18F]-PSMA-1007 PET in April 2022. The image...
Read more Conclusion In our practice, [18F]-PSMA PET/CT has had an important impact on patient care and guiding our treatment decisions. Through our demonstration of diagnostically challenging cases, this educational poster will help to highlight the meaningful, positive impact this modality has in the care of men with prostate cancer. While our demonstration of non-disease related uptake highlight some interesting quirks of the modality that we should be aware of in order to accurately diagnose disease. 
Read more References 1Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018 Jan;38(1):200-17.2Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, Leslie S. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics. 2022 Oct 26;12(11):2594.3Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT, Eiber M. 68Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as...
Read more
GALLERY